CarolAAghajanianMD

Gynecologic Cancer

Chief, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center

Overview of Dr. Aghajanian

Dr. Carol Aghajanian is the Chief of Gynecologic Medical Oncology at Memorial Sloan Kettering Cancer Center and Professor of Medicine, Weill Cornell Medical College, New York, NY.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(323) 649-8101

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1989 - 1992
State University of New York Downstate Medical Center College of MedicineClass of 1989, MD, Cum Laude, Alpha Omega Alpha
Boston UniversityBA, Biology, Summa Cum Laude, Phi Beta Kappa, 1981 - 1985

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 1990 - 2026
NJ State Medical License 2019 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
Top Doctors: New York Metro Area Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2010-2013

Clinical Trials

Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer Start of enrollment: 1997 Jan 01
Completed
Phase 2
Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer Start of enrollment: 2000 Jan 01
Completed
Phase 2
Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer Start of enrollment: 2000 Apr 01
Completed
Phase 2
Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer Start of enrollment: 2001 Nov 05
Completed
Phase 2
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2001 Nov 01
Completed
Phase 1
Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2006 Mar 01
Completed
Phase 2
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Start of enrollment: 2006 Apr 01
Completed
Phase 2
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2008 Sep 01
Completed
Phase 2
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Start of enrollment: 2007 Sep 01
Terminated
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 2
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Start of enrollment: 2011 Mar 01
Completed
Phase 2
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
Active, not recruiting
Phase 2, Phase 3
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients Start of enrollment: 2019 Jan 04
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

42 citations
Machine learning-based prediction of microsatellite instability and high tumor mutation burden from contrast-enhanced computed tomography in endometrial cancers.
Harini Veeraraghavan, Claire F. Friedman, Deborah F. DeLair, Josip Nincevic, Yuki Himoto
Scientific Reports. 2020-10-20
13 citations
Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer.
Ying L Liu, Qin Zhou, Alexia Iasonos, Vivian N. Emengo, Claire F. Friedman
Gynecologic Oncology. 2019-10-01
81 citations
Ovarian cancer mutational processes drive site-specific immune evasion.
Ignacio Vázquez-García, Florian Uhlitz, Nicholas Ceglia, Jamie L P Lim, Michelle Wu
Nature. 2022-12-01

Journal Articles

A Phase 1 Dose-Escalation Study of Intraperitoneal Cisplatin, intravenous/intraperitoneal Paclitaxel, Bevacizumab, and Olaparib for Newly Diagnosed Ovarian Cancer
Karen A Cadoo, Roisin E O'Cearbhaill, Dmitriy Zamarin, Paul J Sabbatini, William P Tew, Carol Aghajanian, Jason A Konner, Gynecologic Oncology
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen Moore, Paul DiSilvestro, Carol Aghajanian, The New England Journal of Medicine

Lectures

Targeted Agents: Finding the Mark
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Evaluation of rucaparib in platinum-sensitive recurrent ovarian carcinoma (rOC) in patients (pts) with or without residual bulky disease at baseline in the ARIEL3 study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Scientific and Clinical Update in Gynecologic Oncology
Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania - 5/3/2013

Press Mentions

Combination of Endometrial Cancer Drugs May Prolong Lives of WomenMarch 31st, 2023
Combining Immunotherapy with Chemo May Help Advanced Endometrial Cancer Patients Live Longer: StudiesMarch 28th, 2023
New Drug Combo Buys More Time for Advanced Endometrial Cancer PatientsMarch 28th, 2023
Join now to see all

Professional Memberships

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment